Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation Academic Article uri icon

Overview

MeSH Major

  • Adenocarcinoma
  • Cancer Vaccines
  • Lung Neoplasms
  • ras Proteins

abstract

  • GI-4000 was well tolerated and immunogenic when used as consolidation therapy in patients with stage I-III KRAS-mutant lung cancer. The patterns of recurrence and death observed in the present study can be used to design a randomized study of GI-4000 with overall survival as the primary endpoint.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.cllc.2014.06.002

PubMed ID

  • 25044103

Additional Document Info

start page

  • 405

end page

  • 10

volume

  • 15

number

  • 6